
Biophytis S.A.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. Specifically, the company is advancing two proprietary drug candidates into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory. The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and collaborates with scientists at the Institute of Myology, and the Vision Institute
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-06-04 07:00 |
Regulatory News Service
Biophytis announces its participation in the BIO International Convention from …
|
English | 155.1 KB | |
2025-06-04 07:00 |
Regulatory News Service
Biophytis annonce sa participation à la BIO International Convention du 16 au 1…
|
French | 161.2 KB | |
2025-05-30 22:00 |
Report Publication Announcement
Information on the Annual Financial Statements
|
English | 103.8 KB | |
2025-05-30 22:00 |
Report Publication Announcement
Information sur les comptes annuels
|
French | 172.5 KB | |
2025-05-15 07:00 |
Regulatory News Service
Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 20…
|
English | 144.3 KB | |
2025-05-15 07:00 |
Regulatory News Service
Biophytis met en lumière son approche innovante du traitement de l’obésité lors…
|
French | 129.9 KB | |
2025-04-22 07:00 |
Regulatory News Service
Biophytis cible la restauration de la mobilité chez les patients obèses
|
French | 143.1 KB | |
2025-04-22 07:00 |
Regulatory News Service
Biophytis targets mobility restoration in patients with obesity
|
English | 140.1 KB | |
2025-04-09 07:00 |
Regulatory News Service
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
|
English | 175.0 KB | |
2025-04-09 07:00 |
Regulatory News Service
Biophytis confirme le lancement de l’essai clinique de Phase 2 OBA dans l’obési…
|
French | 169.7 KB | |
2025-03-28 22:00 |
Capital/Financing Update
Biophytis announces the settlement and delivery of its €2.6 million private pla…
|
English | 534.3 KB | |
2025-03-28 22:00 |
Capital/Financing Update
Biophytis annonce le règlement-livraison de son placement privé de 2,6 millions…
|
French | 340.2 KB | |
2025-03-26 07:35 |
Capital/Financing Update
Biophytis announces the successful completion of a €2,6 million private placeme…
|
English | 381.7 KB | |
2025-03-26 07:35 |
Share Issue/Capital Change
Biophytis annonce le succès d'un placement privé d'environ 2,6 millions d'euros
|
French | 381.0 KB | |
2025-03-24 07:30 |
Inside Information Statement
Biophytis announces new non-clinical data further supporting its mission to pio…
|
English | 242.6 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
2020-12-16 | N/A | Other | Other | 313,417 | N/A |
2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
1NKEMIA | Spain | IKM | |
![]() |
2cureX AB | Sweden | 2CUREX | |
![]() |
4SC AG | Germany | VSC | |
![]() |
Abera Bioscience AB | Sweden | ABERA | |
![]() |
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
![]() |
AB Science | France | AB | |
![]() |
Acticor Biotech | France | ALACT | |
![]() |
Active Biotech | Sweden | ACTI | |
![]() |
AcuCort AB | Sweden | ACUC |